The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AYA | +320.99% | N/A | N/A | +114% |
| S&P | +13.95% | +78.35% | +12.25% | +51% |
Artrya Ltd. develops the Salix suite of products to address coronary artery disease (CAD). It uses artificial intelligence (AI) to improve the detection and management of coronary artery disease. The company was founded by John Windsor Barrington and John Konstantopoulos on January 24, 2018 and is headquartered in West Perth, Australia.
No news articles found for Artrya.
No data available for this period.
Currently no data to display
Currently no data to display.
Currently no data to display.
No data available for this period.
No data available for this period.
No data available for this period.
No data available for this period.
| Metric | YoY Change |
|---|
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
